Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Operating Cash Flow
Cash generated by the company's core business operations during the period.
Surrozen, Inc.NASDAQ: SRZN
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $12.5M (cash outflow) rose 34.7% year over year, behind the +84.2% change in trailing-twelve-month operating cash flow. Sequentially, it rose 115.0% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Operating cash flow amounted to 869.8% of revenue in FY2025, up 704.4 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +34.7% toward the trailing-twelve-month pace of +84.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (30.24M) USD
- Year-over-year change
- -71.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.24M) | -71.6% |
| FY2024 | 2024-12-31 | (17.63M) | +56.3% |
| FY2023 | 2023-12-31 | (40.36M) | +8.6% |
| FY2022 | 2022-12-31 | (44.15M) | +9.6% |
| FY2021 | 2021-12-31 | (48.81M) | — |
Operating Cash Flow vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 operating cash flow of $33.46M is the 5th largest of the 8 companies compared; the peer median is $33.76M.
- Its year-over-year change of +84.2% is the 2nd highest of 8, against a peer median of +3.0%.
- Operating cash flow amounts to 446.5% of revenue for SRZN, versus a peer median of 322.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.53M | -39.9% | -3.4% | 70.7% | |
| LTM Mar 2026 | $48.47M | +3.0% | -9.9% | 322.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $38.99M | +35.1% | — | 325.3% |
| LTM Mar 2026 | $33.76M | -25.8% | -41.2% | — | |
| LTM Mar 2026 | $33.46M | +84.2% | -11.8% | 446.5% | |
| LTM Mar 2026 | $32.07M | +157.5% | +47.8% | — | |
| LTM Mar 2026 | $20.25M | -34.9% | +9.9% | — | |
| LTM Mar 2026 | $12.78M | +74.6% | +16.9% | — | |
| Peer median (excluding SRZN) | $33.76M | +3.0% | +3.3% | 322.3% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Depreciation & Amortization | 2.07M | 1.96M | 1.91M | 1.44M | 537K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.32M | 4.52M | 4.37M | 4.11M | 3.84M |
| Change in Working Capital | (221K) | (8.42M) | (3.93M) | (836K) | 3.15M |
| Accounts Receivables | 0 | (1.98M) | 0 | (502K) | 2.33M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857K | (2.04M) | (133K) | (228K) | 142K |
| Other Working Capital | (1.08M) | (4.4M) | (3.8M) | (106K) | 678K |
| Other Non-Cash Items | 1.67M | (6.2M) | 325K | 41.22M | 204.26M |
| Operating Cash Flow | (48.81M) | (44.15M) | (40.36M) | (17.63M) | (30.24M) |
| Capital Expenditures | (1.27M) | (728K) | (398K) | (26K) | (128K) |
| Acquisitions (Net) | 0 | (39.04M) | 0 | 0 | 0 |
| Purchases of Investments | (91.74M) | (29.6M) | (28.04M) | 0 | 0 |
| Sales of Investments | 15.3M | 68.64M | 80.17M | 0 | 0 |
| Other Investing Activities | 0 | 39.04M | 0 | 0 | 0 |
| Investing Cash Flow | (77.71M) | 38.31M | 51.72M | (26K) | (128K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 124.22M | 42K | 280K | 16.04M | 85.05M |
| Common Stock Repurchased | 0 | (2.61M) | (4K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 410K | (85K) | 280K | 133K | 0 |
| Financing Cash Flow | 124.63M | (2.57M) | 276K | 16.18M | 85.05M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.89M) | (8.4M) | 11.64M | (1.48M) | 54.68M |
| Free Cash Flow | (50.08M) | (44.87M) | (40.76M) | (17.65M) | (30.37M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.